Chromogranin A is a Sensitive Marker of Progression or Regression

#601

Introduction: One of the most common is gastroenteropancreatic (GEP) NET of the pancreas, which constitute about 30% of all GEP NET. CgA is an excellent marker for NET and tumor volume and plasma CgA is suggested as the most reliable marker in follow-up of GEP but only few studies have been published.

Aim(s): We investigated the diagnostic accuracy of plasma CgA as a predictor for progression, regression or stable disease compared to changes on CT scan in 76 patients with CgA positive pancreatic NET.

Materials and methods: Each patient was evaluated by events. An event was recorded when a CT scan was followed by another corresponding scan together with a hCgA(340-348). Change in tumor burden was defined as regression, progression or stable disease using RECIST criteria 1.1.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Jensen K

Authors: Jensen K, Hilsted L, Andersen J, Mynster T, Rehfeld J,

Keywords: Chromogranin A, pancreatic neuroendocrine tumors, neuroendocrine tumors, computered tomography, RECIST 1.1, radioimmunoassay,